Chemistry at the Core
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
Built for Patients
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
Driven by Purpose
We are passionate about using our expertise to address the needs of patients with cancer.
Ruth Adams
Vice President, Clinical Operations
Jason Agostinelli
Finance
Kari Andrews
Clinical
Kristin Andrews, PhD
Chemistry
Ingrid Armstrong, MS
Clinical
Alex Balcom, MBA, CPA
Chief Financial Officer
Leah Bennis, MPA
Regulatory Affairs
Josh Bergren
Commercial
Jessica Bond
Pharmaceutical Development
Jim Burgeson, MS
Pharmaceutical Development
Kristi Byrnes
Quality
Matthew Campbell
Pharmaceutical Development
Liz Candido
Operations
Stephanie Ceballos
Information Technology
Smruti Chaudhari, PhD
Pharmaceutical Development
Sibao Chen, PhD
Pharmaceutical Development
Paula Chubet
Legal
Christopher Cooper, PhD
Pharmaceutical Development
Leah Crabtree, CPA
Finance
Jess Crespo, CPA
Finance
Steve Critchley
Pharmaceutical Development
Shannon Dauksis, PharmD
Program Management
Rachel DeLaRosa, RN
Clinical
Karen Ellis
Program Management
Philip Engel
Information Technology
Jenn Fairbanks
Clinical
Wenzhe Fan, PhD
Pharmaceutical Development
Scott Faulhaber, MBA
Clinical Supply Chain
Megan Flynn
Medical Affairs
Jesus Garza, MA
Finance
Baudouin Gerard, PhD
Pharmaceutical Development
Tina Gibson, MS
Quality
Nurisha Gobin, PharmD, MBA, RPh
Regulatory Affairs
Andrew Havens
Legal
Sophie Higgins, MPH
Regulatory Affairs
Lisa Holland, MBA, MSN
Commercial
Joshua Horan, PhD
Vice President, Chemistry
Brett Hubbard, RN
Clinical
Tina Kehrig
Clinical
Ray Kemper, PhD, DABT
Translational Development
Gloria (Glo) Kennedy, RN
Clinical
Jason Kropp
Pharmaceutical Development
Shashank Kulkarni, PhD
Chemistry
Joshua Lance, JD
Legal
Benjamin Lane, PhD
Senior Vice President, Technical Operations
Melissa Laurie, PharmD, MS, MBA
Medical Affairs
Lidya Le
Clinical
Jeffrey Lee
Information Technology
Megan Lichtenfels, CPA
Finance
Jessie Lin
Vice President, Corporate Strategy & Portfolio Management
Chelcie Lister
Corporate Development
Mei Liu, PhD
Clinical
Allison Magnan
Quality
Joseph Magrino, PhD
Biology
Ren Main
Finance
Morgan Maiola, MS
Quality
Sowjanya Mangipudi, MS
Clinical
Steve Margossian, MD, PhD
Clinical
Christian Martin
Translational Development
Sammy Al-Masri, MS
Regulatory Affairs
Nathan McConarty, JD
Legal
Scot Mente, PhD
Chemistry
Matthew Metivier, MBA
Senior Vice President,
Human Resources
Human Resources
Deb Miller, MMSc, PhD, JD
Chief Legal Officer
Tuan Minh Nguyen, PhD
Biology
Megan Montgomery, PhD
Medical Affairs
Kevin Newkirk
Program Management
Victoria Nigro, MBA, MS
Clinical Supply Chain
Darlene Noci, ALM
Chief Development Officer
Matthew O’Connor
Clinical
Lorina Ouimette
Clinical
Marco Palencia
Clinical
Natalia Pascucci, MBA
Clinical
Meghavi Patel
Pharmaceutical Development
Henry Pelish, PhD
Chief Scientific Officer
James Porter, PhD
Chief Executive Officer
Bob Prytko, MSc
Pharmaceutical Development
Gosia Riley, MA
Clinical
José Rios Lizarraga, PhD
Pharmaceutical Development
Amy Rochford
Clinical
Paula Rothwell
Clinical Supply Chain
Mikhaila Ruth
Human Resources
Prabjyot Sachdev
Corporate Development
Manoj Samant, PhD
Clinical
Danieska Sandino, MBA
Clinical
Christine Schneeberg
Clinical Supply Chain
Maureen Secord
Clinical Supply Chain
Jimmy Shannon
Quality
Ally Shou, PhD, JD
Legal
Jacob Sizemore, PhD
Pharmaceutical Development
Greg Smith, MS
Regulatory Affairs
John Soglia, PhD
Senior Vice President, Translational Development
Kevin Staffin
Quality
Yuting Sun, PhD
Biology
Wint Swe, MBBS, MBA
Clinical
Anupong Tangpeerachaikul, PhD
Biology
Seth Taylor
Quality
Christopher Turner, MD
Chief Medical Officer
Vivek Upadhyay, MD, MBI
Clinical
Virginia Vetter, MS
Regulatory Affairs
Brenda Vienneau, CPA, CMA
Finance
Morgan Walker, PhD
Pharmaceutical Development
Michael Walsh, PhD
Biology
Stacia Wegst-Uhrich, PhD
Pharmaceutical Development
Carla Whalen
Human Resources
Brett Williams, PhD
Chemistry
Lindsey Wilson, MS
Clinical
Jimmy Yung
Finance
Viola Zhu, MD, PhD
Clinical
Fareya Zubair, MS
Regulatory Affairs
Anticipated initiation in the first half of 2025: A Phase 3 randomized, controlled study of NVL-655 versus alectinib for patients with TKI-naive ALK-positive NSCLC
Read the latest news
